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Hypoxia is a common feature of tumors and an important contrib-
utor to malignancy and treatment resistance. The ability of tumor
cells to survive hypoxic stress is mediated in part by hypoxia-
inducible factor (HIF)-dependent transcriptional responses. More
severe hypoxia activates endoplasmatic reticulum stress responses,
including the double-stranded RNA-activated protein kinase (PKR)-
like endoplasmic reticulumkinase (PERK)/eukaryotic initiation factor
2α (eIF2α)-dependent arm of the unfolded protein response (UPR).
Although several studies implicate important roles for HIF and UPR
in adaption to hypoxia, their importance for hypoxic cells responsi-
ble for therapy resistance in tumors is unknown. By using isogenic
models, we find that HIF and eIF2α signaling contribute to the sur-
vival of hypoxic cells in vitro and in vivo. However, the eIF2α-de-
pendent arm of the UPR is uniquely required for the survival of
a subset of hypoxic cells that determine tumor radioresistance. We
demonstrate that eIF2α signaling induces uptake of cysteine, gluta-
thione synthesis, and protection against reactive oxygen species
produced during periods of cycling hypoxia. Together these data
imply that eIF2α signaling is a critical contributor to the tolerance
of therapy-resistant cells that arise as a consequence of transient
changes in oxygenation in solid tumors and thus a therapeutic tar-
get in curative treatments for solid cancers.
growth delay | irradiation | acute hypoxia
Solid tumor microenvironments are characterized by extremeheterogeneities in oxygenation that arise as a result of poorly
developed vascular networks. Gradients in oxygen are frequently
found surrounding perfused vessels, ranging from normal values
(∼5%) near the blood vessel to complete anoxia adjacent to ne-
crosis. This gradient of hypoxia is generally referred to as “chronic”
or “diffusion-limited” hypoxia and results from cellular oxygen
consumption. Hypoxia can also arise in a temporal manner as
a consequence of transient changes in oxygen delivery caused by
changes in vessel perfusion (1). This “acute” or “perfusion-limited”
hypoxia (2) is often cyclic in nature and can account for a large
proportion of hypoxic cells at any given time (3). The steady-state
proportion of hypoxic cells in tumors is influenced by the tolerance
of individual tumor cells to these different types of hypoxia and
varies remarkably among tumors with otherwise similar clinical
features (4). For example, in head and neck cancer, oxygen elec-
trodemeasurements of the hypoxic fraction range from 0% to 97%
(5). These differences are important, because the fraction of viable
hypoxic cells is a major determinant of outcome, as hypoxic cells
are highly resistant to chemotherapy and radiation therapy (5, 6).
Reducing cellular tolerance to hypoxia is therefore a strategy to
reduce the proportion of hypoxic cells in tumors to improve cur-
rent cancer therapy.
The mechanisms influencing hypoxia tolerance and therapy
resistance in solid tumors are only partially understood. Hypoxia-
inducible factor (HIF) transcription factors promote hypoxia
tolerance through activation of a large number of genes that
influence cellular metabolism and pH regulation (7, 8). In ad-
dition, HIFs influence tumor oxygenation directly by promoting
angiogenesis, endothelial cell survival, and vasculogenesis (7, 9–
13). Stabilization of HIF and activation of its downstream sig-
naling pathways occurs at relatively moderate levels of hypoxia
(<2% O2) (14), which is considerably higher than that required
to produce radiation resistance (<0.2%) (15).
More severe hypoxia (<0.2%O2) leads to rapid activation of the
unfolded protein response (UPR) (14). This is an evolutionarily
conserved pathway that responds to endoplasmatic reticulum
(ER) stress by the coordinate action of three ER stress sensors
present within the ER membrane, PERK (EIF2AK3), inositol
requiring kinase 1 (IRE1/ERN1), and activating transcription
factor 6 (ATF6) (16). These are activated through a common
mechanism involving sequestration of BIP (HSPA5) by misfolded
proteins from the luminal domains of the sensors. The kinase
PERK phosphorylates the serine 51 residue of eukaryotic initia-
tion factor 2α (eIF2α) to inhibit mRNA translation. In addition to
an overall inhibition in protein synthesis, eIF2α phosphorylation
redirects translation toward a subset of transcripts, including the
transcription factor ATF4 (17, 18). eIF2α phosphorylation and
inhibition of mRNA translation is transient because ATF4 induces
a second transcription factor, C/EBP homologous protein (CHOP/
DDIT3), which in turn regulates expression of growth arrest and
DNA damage gene 34 (GADD34/PP1R15A), which dephos-
phorylates eIF2α and completes a negative feedback loop to re-
store protein synthesis (19). Hypoxic activation of PERK is of
functional importance because PERK-KO mouse embryonic
fibroblasts (MEFs) or MEFs with a knock-in eIF2α mutant allele
containing a serine-to-alaninemutation at position 51 (S51A) (20),
show increased cell death during hypoxia and produce slow-
growing tumors with reduced regions of viable hypoxia (21). Fur-
thermore, PERK signaling is essential for the survival of hypoxic
cells by preserving the cells’ capacity to maintain high rates of
autophagy (22). Abrogation of PERK-mediated signaling results
in loss of autophagic capacity and sensitizes cells to hypoxia-
induced cell death.
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Although PERK/eIF2α andHIF pathways have been implicated
by several studies in hypoxia tolerance, they show clear differences
in oxygen levels required for their activation. It is unknown to what
degree these two pathways contribute differentially to long-term
survival of hypoxic cells in tumors responsible for treatment fail-
ure. We have investigated this question by using inducible and
isogenic tumor models, and our data reveal an essential role for
PERK/eIF2α signaling that promotes the survival of radiation-
resistant hypoxic cells by stimulating glutathione (GSH) synthesis
and reducing reactive oxygen species (ROS) produced during
cyclic acute hypoxia.
Results
eIF2α Signaling Is Required for Hypoxic Cell Survival. To investigate
the role of HIF and UPR/PERK/eIF2α signaling on growth and
hypoxia tolerance, we constructed isogenic sets of U373 and
HCT116 cells expressing inducible interfering transgenes at a sin-
gle genomic location (23, 24). eIF2α signaling inhibition is ach-
ieved through expression of the C-terminal region of hamster
GADD34 (GADD34c; Fig. S1A) or a dominant-negative eIF2α
allele (eIF2αS51A; Fig. 1A). Both approaches effectively prevent
phosphorylation of eIF2α and expression of the downstream UPR
target genes CHOP and GADD34 in U373 lines after exposure to
hypoxia (Fig. 1 A and B) (25). Similar to previous results, knock-
down experiments demonstrated that eIF2α phosphorylation
during hypoxia in these cells is dependent on PERK (20, 21, 23,
26), although these cells also show some dependency on general
control nonrepressed 2 (GCN2) (Fig. S2). As shown previously
(23), inhibition of eIF2α signaling by either approach had no in-
fluence on cell proliferation under normal conditions or during
moderate hypoxia (0.2%O2; Fig. 1C and Fig. S1C). Severe hypoxia
(<0.02% O2) caused a decrease in cell number in eIF2α signaling-
deficient cells, suggestive of increased cell death. We therefore
determined hypoxia tolerance by measuring long-term clonogenic
survival following exposures to moderate (0.2% O2) or severe
(<0.02% O2) hypoxia. Interestingly, inhibition of eIF2α signaling
markedly reduced overall survival in U373 (Fig. 1D) and HCT116
(Fig. S1B) cell lines following exposure to severe and moderate
hypoxia. Overexpressing GADD34c or eIF2α(S51A) had no ef-
fect on colony formation under ambient oxygen conditions and
does not alter HIF-1α induction or HIF-dependent gene expres-
sion (Fig. S3) (27).
eIF2α Signaling Promotes Hypoxia Tolerance in Vivo but Not Overall
Tumor Growth. To assess the importance of eIF2α signaling on
hypoxia tolerance and growth in a more relevant context, we
exploited the ability to inducibly inhibit this pathway in established
tumor xenografts. Groups ofmice were injected with the PCDNA5
control or GADD34c or eIF2αS51A inducible isogenic lines and
allowed to form xenografts of ∼150 mm3. As in cell culture,
doxycycline administration resulted in effective functional disrup-
tion of eIF2α signaling in vivo, as evidenced by reduced phospho-
eIF2α (p-eIF2α) staining (Fig. S4C). In addition, we observed a de-
crease in CHOP and endogenous GADD34 mRNA expression in
tumors from the doxycycline-treated GADD34c and eIF2αS51A
models [P < 0.01 and P < 0.05 in GADD34c and eIF2α(S51A) for
CHOP and GADD34, respectively; Fig. S4C]. However, disruption
of eIF2α signaling after tumor establishment had no significant
effect on overall tumor growth (Fig. S4 A and B). This contrasts
with the effects of disrupting eIF2α signaling before tumor initia-
tion, which significantly slows tumor establishment (see Fig. 4B) as
also shown previously (21).
To assess the effect of eIF2α inhibition on hypoxia tolerance in
vivo, we analyzed the microenvironments of established U373
tumors following administration of doxycycline for 7 d. Strik-
ingly, an almost twofold reduction in the fraction of viable hyp-
oxic tissue was observed in the GADD34c and eIF2αS51A
tumors (P < 0.05; Fig. 2 A and C). This reduction was associated
with a significant increase in necrosis in the GADD34c and
eIF2αS51A tumors, respectively (P < 0.05; Fig. 2 B and D).
Other microenvironmental features, including vessel density and
overall cell proliferation, remained unchanged (Fig. S4D).
eIF2α Signaling Promotes Survival of Therapy-Resistant Cells. Hyp-
oxic cells are a major limiting factor in the efficacy of radiation
therapy, as they require nearly three times as much radiation as
nonhypoxic cells for equivalent cell kill. We thus determined the
radiation response of established U373 tumors following eIF2α
inhibition. Tumors were treated with or without doxycycline and
then irradiated with a single dose of 15 Gy. This dose kills the vast
majority of nonhypoxic cells (>99.999%), but not hypoxic cells
(∼0.5% survive; Fig. 3C). As a consequence, the tumor growth
delay closely reflects the number of long-term viable hypoxic cells
present at the time of irradiation. Treatment with 15 Gy resulted in
a significant growth delay in all groups (Fig. 3A). In the absence of
doxycycline, no differences in radiation sensitivity were observed
between tumor types (Fig. 3A, Left). However, transient eIF2α
inhibition before irradiation in the GADD34c and eIF2αS51A
models increased radiation response, with many tumors failing to
regrow within 90 d of follow-up (Fig. 3A, Middle). Consistent
with a direct effect on the viability of radiation-resistant hypoxic
cells, this sensitization required inhibition of eIF2α before irradi-
ation; no synergy was observed when eIF2α was inhibited after
radiation treatment (Fig. 3A, Right).
To illustrate the differences in radiation sensitivity of the in-
dividual tumors, the data are replotted in Fig. 3B as Kaplan–
Meier plots. Assessed in this way, radiation treatment can be
observed to extend the median survival of mice with PCDNA5
control tumors from 30 to 47 d irrespective of doxycycline
treatment (P < 0.05; Fig. 3B, Left). In contrast, both PERK/
UPR-deficient models show a dramatic increase in survival when
irradiated, when eIF2α signaling is targeted before irradiation. In
these doxycycline-treated groups, the eIF2αS51A and GADD34c
unirradiated mice have a median survival similar to PCDNA5
controls (∼30 d), whereas 100% (P < 0.01; Fig. 3B, Middle) and
60% (P < 0.05; Fig. 3B, Right) of mice survive for >90 d, re-
spectively, when irradiated.
Regardless of eIF2α status, all cell lines showed a similar ra-
diation response in vitro, and, as expected, hypoxic cells required
∼2.5 to threefold more dose for equivalent toxicity (Fig. 3C).
These data indicate that the decrease in hypoxic fraction before
Fig. 1. PERK/UPR is required for hypoxic cell survival. (A) p-eIF2α immunoblot
of isogenic, doxycycline (dox)-inducible U373 cells with control [pCDNA5(+)],
and PERK/UPR interfering genes (GADD34c and eIF2αS51A) after hypoxia
(O2 < 0.02) exposure. (B) Quantitative PCR for CHOP and endogenous GADD34
after 8 h hypoxia (O2 < 0.02%) exposure of doxycycline-pretreated (16 h) U373
cell lines. (C) Growth curve of U373 cells under normal (Left) or 0.2% oxygen
(Right). (D) Clonogenic survival of control and PERK/UPR-deficient cells under
severe (O2 < 0.02%) and moderate (0.2% O2) hypoxia.










































irradiation is the primary cause of improved response to radi-
ation in vivo.
Comparison of HIF-1 and eIF2α Signaling Pathways on Hypoxia
Tolerance and Therapy Resistance. To compare the relative impor-
tance of eIF2α with that of theHIF pathway, we generated isogenic
HCT116 cell lines with regulated expression of GADD34c,
eIF2αS51A, and an shRNA directed against HIF-1α (shHIF-1α).
We were unable to generate a similar functional U373 shHIF-1α
line as a result of higher endogenous expression levels of HIF-1α.
Doxycycline exposure in the shHIF-1α HCT116 line prevented
accumulation of HIF-1α protein under hypoxic conditions (Fig.
S5A) and reduced HIF transcriptional targets, including carbonic
anhydrase 9 (CA9), vascular endothelial growth factor (VEGF),
and glucose transporter 1 (Glut1) (Fig. S5B). Knockdown of HIF-
1α also reduced hypoxia tolerance as assessed by clonogenic sur-
vival in response to severe (<0.02% O2) and moderate (0.2% O2)
hypoxia, and these effects were similar to that observed following
eIF2α inhibition in this cell line (Fig. S5D and Fig. S1B). In-
terestingly, HIF-1α knockdown also reduced proliferation under
moderate hypoxia (0.2% O2; Fig. S5C), in contrast to eIF2α
inhibition (Fig. S1C).
The importance of inhibiting eIF2α was then compared with
inhibiting HIF-1α during or after xenograft establishment in mice.
Continuous administration of doxycycline starting at tumor im-
plantation showed that initiation of xenografts from eIF2α sig-
naling deficient lines was slightly delayed (P < 0.01; Fig. 4 A and
B), but, when they had been established, grew at rates comparable
to the PCDNA5 controls (Fig. 4C). A much longer delay was
observed for initiation of HIF-1α–deficient tumors (P < 0.001);
however, when they had been established, they grew slightly faster
than control or UPR-deficient tumors (doubling time, 6.9 d vs. 7.5
d and 7.6 d for the two eIF2α-deficient models; P < 0.05; Fig. 4C).
Inhibition of eIF2α signaling or HIF-1α after xenograft estab-
lishment had no effect on tumor growth or doubling time of the
tumors (Fig. 4 D and E). Thus, HIF and, to some extent, eIF2α
signaling are important for initial engraftment and tumor initia-
tion, but are not required for tumor growth after establishment.
Similar to results in the U373 tumors, 7 d of doxycycline
treatment resulted in a decrease in the hypoxic fraction (P < 0.05;
Fig. 4F) in the eIF2α-signaling deficient models (from 41% to
23%). Inhibition of HIF-1α in the established tumors also resulted
in a similar decrease in the hypoxic fraction from 41% to 25% (P<
0.05; Fig. 4F).
Finally, we compared the therapeutic relevance of the de-
crease in hypoxic fraction following inhibition of HIF-1α or
eIF2α in these isogenic models. Surprisingly, unlike the effects of
inhibiting eIF2α, the reduction in hypoxia following knockdown
of HIF-1α did not increase the sensitivity of these tumors to ir-
radiation (Fig. 4 G and H). Thus, although HIF-1α supports the
survival of a population of hypoxic cells, this population appears
distinct from that which contributes to radiation resistance.
Similar to the U373 isogenic cells, no difference in the radiation
sensitivity of the shHIF-1α– or eIF2α-deficient lines was ob-
served in vitro.
In contrast, HIF-1α silencing after irradiation caused a large
delay in rate of regrowth (P < 0.05; Fig. 4 G and H). This effect
was not observed in either of the GADD34c or eIF2αS51A
tumors (Fig. 3 A and B and Fig. S5 E and F).
Fig. 2. PERK/UPR inhibition reduces the tumor hypoxic fraction. (A) Pimo-
nidazole (pimo) immunohistochemistry (pimonidazole positive viable frac-
tion, green; blood vessels, red; Hoechst dye, blue) and (B) H&E on U373
isogenic tumors. (C) Quantification of pimonidazole immunohistochemistry
of the viable tumor tissue and (D) necrotic fraction.
Fig. 3. PERK/UPR targeting before irradiation sensitizes tumors to irradiation. Established U373 isogenic xenografts were irradiated (t = 0) when indicated
(15 Gy) at ∼150 mm3. (A) (Left) No doxycycline (dox) was administered to the animals [mean ± SEM; pCDNA5(+), n = 5; GADD34c, n = 6; eIF2αS51A, n = 6).
Regular growth of the tumors without irradiation (dotted lines). (Center) Doxycycline was administered for 7 d [t = −4 to t = 3, irradiation at t = 0; mean ±
SEM; pCDNA5(+), n = 6; GADD34c, n = 10; eIF2αS51A, n = 6]. (Right) Doxycycline administration after irradiation [t = 0; mean ± SEM; pCDNA5(+), n = 8;
GADD34c, n = 9; eIF2αS51A, n = 11]. (B) Kaplan–Meier survival for tumors in Fig. 3A and Fig. S4A to reach four times the initial volume after regular growth
(dotted lines) or irradiation without (black line) or with doxycycline administration (doxycycline from t = −4 to t = 3, irradiation at t = 0, green line;
doxycycline after irradiation, red line). (C) Clonogenic survival cells after irradiation under normal and hypoxic (O2 < 0.02%) conditions.



































eIF2α-Signaling Deficient, but Not HIF-Deficient, Cells Are Sensitized
to Cyclic Hypoxia. As inhibition of HIF-1α and eIF2α signaling
resulted in a similar decrease in tumor hypoxia (i.e., pimonidazole-
positive cells) but had different consequences on radiation re-
sponse, we hypothesized that these pathways may promote sur-
vival of cells that become hypoxic through different mechanisms
(i.e., acute or chronic hypoxia) (28). To assess the sensitivity of
cells to acute hypoxia, we measured clonogenic survival after
repeated cycles of severe hypoxia (1 h, O2 < 0.02%) followed by
reoxygenation (1 h). Whereas the HIF-deficient cells displayed
a comparable sensitivity as the control cells, both eIF2α signaling-
deficient lines were markedly sensitized to cycling hypoxia (Fig.
5A). Reoxygenation following hypoxia can cause generation of
ROS, which contribute to the toxicity of cycling hypoxia (29).
Indeed, the eIF2α signaling-deficient cells had approximately
twofold higher levels of ROS during cycling hypoxia (Fig. 5B).
Importantly, elevated ROS in these cells are specific to cyclic
hypoxic stress as ROS levels were similar in control and eIF2α
signaling-deficient cells under aerobic conditions and following
irradiation (Fig. S6A). Furthermore, no differences were observed
in the toxicity generated by exposure to ROS inducing agents
(Fig. S6B).
PERK activation during the UPR has been shown to result
in phosphorylation and activation of nuclear factor (erythroid-
derived 2)-like 2 (NRF2), a master regulatory of the antioxidant
response. Although this appears to occur in an eIF2α-in-
dependent manner (30), we tested if differences in NRF2 acti-
vation could explain differences in ROS levels and toxicity of
cyclic hypoxia in our models. However, we observed no differ-
ences in nuclear translocation of an NRF2 reporter, or activation
of NRF2 endogenous transcriptional targets between control and
eIF2α signaling-deficient cells (Fig. S7 A and B). Furthermore,
knockdown of Kelch like-ECH-associated protein 1 (KEAP1),
and thus activation of NRF2, was unable to rescue the sensitivity
of eIF2α signaling-deficient cells to cyclic hypoxia (Fig. S7 C
and D).
To test the importance of elevated ROS on hypoxia tolerance,
we treated cells with the ROS scavenger, N-acetylcysteine (NAC)
during cyclic hypoxia. NAC treatment prevented ROS generation
and toxicity in all isogenic lines (Fig. 5C). These data indicate that
eIF2α signaling plays an important role in mitigating the pro-
duction or effects of ROS during cycling hypoxia.
eIF2α signaling has previously been implicated in mediating
resistance to oxidative stress (31) by increasing intracellular cys-
teine and GSH synthesis. Increased cysteine levels are mediated
through eIF2α- and ATF4-dependent expression of cystine/glu-
tamate transporter xCT (SLC7A11) (32), a subunit specific to the
cystine/glutamate antiporter system Xc−, as well as cystathione
γ-lyase (CTH), which produces intracellular cysteine from
serine- and homocysteine-derived cystathione (33). We found
that, in control cells, xCT and CTH are induced during cyclic
hypoxia (Fig. 5D), whereas, in eIF2α signaling-deficient cells, basal
expression is decreased and the cyclic hypoxia-induced increase is
entirely prevented. Similar results were obtained for γ-gluta-
mylcysteine synthetase (Fig. S8A), the first and rate-limiting en-
zyme for GSH synthesis. The nonspecific subunit of Xc−, SLC3A2,
and GSH synthetase are not dependent on eIF2α signaling.
Consistent with these defects, we found that eIF2α signaling-
deficient cells have decreased levels of total glutathione (GSH and
oxidized GSH; GSSG; Fig. 5E, Left). Furthermore, when exposed
to cycling hypoxia, these cells are insufficient to maintain a stable
pool of “free” GSH to react with oxidizing agents (Fig. 5E, Right).
In contrast, cells with intact eIF2α signaling, which induce cysteine
transporters and GSH biogenesis enzymes, had increased free
GSH after exposure to cyclic hypoxia. Preincubation with NAC
increased GSH synthesis in all cell lines and rescued free GSH
levels in eIF2α signaling-deficient cells during cyclic hypoxia.
Similar results were obtained in U373 cells (Fig. S8B). These data
demonstrate that the increased ROS and cell death observed
in the eIF2α signaling-deficient cells reflects a defect in responding
to cyclic hypoxia by increasing intracellular cysteine and GSH
synthesis.
Discussion
Hypoxia is a common but heterogeneous feature of solid tumors
and a major limiting factor in successful cancer treatment (7).
Although this has been known for some time, the basis for the
wide variation in the levels of hypoxia and their influence on
treatment outcome among patients’ tumors is still poorly un-
derstood. The proportion of viable cells at various different oxy-
gen concentrations within individual tumors is influenced by
deficiencies in oxygen delivery (inadequate vessel development
and/or function) and by differences in cellular tolerance to hyp-
oxia. The ability of tumor cells to survive moderate or severe
levels of hypoxia is strongly influenced by adaptive mechanisms
including HIF and eIF2α pathway. Here, by using inducible and
isogenic models, we show that, even though both of these path-
ways influence hypoxic levels in tumors, the eIF2α pathway is
uniquely important for the survival of a subset of hypoxic cells in
established tumors that are radiation-resistant and can contribute
to regrowth of the tumor following treatment.
Fig. 4. PERK/UPR and HIF deficiency delays tumor formation. (A) Tumor
growth of s.c. implanted isogenic HCT116 cells targeting HIF-1α (i.e., shHIF-
1α), GADD34c, and control cells [pCDNA5(+)] preexposed (24 h) to doxycy-
cline (dox) were injected into doxycycline receiving nude mice [mean ± SEM,
pCDNA5(+), n = 6; GADD34c, n = 8; shHIF-1α, n = 8]. (B) Palpability (>60
mm3) of tumors. (C) Doubling time of individual tumors. (D) After estab-
lishment (150 mm3), mice received doxycycline in their drinking water
[mean ± SEM; pCDNA5(+), n = 10; GADD34c, n = 7; shHIF-1α, n = 10]. (E)
Doubling time of the individual tumors. (F) Tumors were harvested after 7 d
doxycycline, and hypoxia was assessed by pimonidazole immunohistochem-
istry of the viable tumor tissue. (G) Mice with established tumors (150 mm3)
received doxycycline in drinking water. Growth (dotted lines) and regrowth
after irradiation (t = 0) was followed over time in animals that received no
doxycycline (−dox, n = 7) or doxycycline from day −4 to day +3 [+dox 7 d
(10 Gy), n = 8] or doxycycline after irradiation [+dox after irradiation (10 Gy),
n = 10]. (H) Kaplan–Meier survival for tumors in Fig. 4 D and G to with the
endpoint of reaching four times the initial volume.










































It is clear that the hypoxic fraction of cells within tumors contains
subpopulations with different biological phenotypes and unique
contributions to therapy resistance. The overall hypoxic fraction, as
measured by pimonidazole, was equally decreased in tumors fol-
lowing inducible inhibition of eIF2α or HIF-1 pathways in estab-
lished tumors. However, the decrease that occurred following
transient inhibition of HIF did not result in an improved tumor
response to radiation therapy. The consequence of HIF inhibition
on steady-state levels of moderate or severely hypoxic cells in
tumors is complex and difficult to predict. It is likely that HIF sig-
naling directly supports the survival of some cells in response to
chronic hypoxia exposure, as loss of HIF reduced survival and
proliferation of these same cells to long exposures of moderate or
severe hypoxia. However, HIF also inhibits (i) mitochondrial oxy-
gen consumption by inducing PDK1 and (ii) tumor oxygen delivery
by inducing angiogenesis. Thus, demand and supply of oxygen are
altered following HIF inhibition in vivo. Our data indicate that
transient HIF inhibition does not substantially alter the fraction of
radiation-resistant cells. In contrast, inhibition of HIF in the same
model after radiation treatment resulted in a marked delay of tu-
mor growth. These results are consistent with previously reported
effects of the HIF small-molecule inhibitor YC-1, which, when
given before radiation therapy, inhibits radiation response, whereas
treatment afterward enhances response (34). Several other recent
publications have confirmed in the context of radiation treatment
outcome that HIF signaling is primarily important for driving re-
covery of tumor vasculature in the hypoxic microenvironment fol-
lowing therapy-induced vessel damage (12, 13).
In contrast, our data demonstrate a critical role for eIF2α sig-
naling in promoting survival of a therapy-relevant fraction of
hypoxic cells. Inducible inhibition of eIF2α signaling reduced the
pimonidazole-positive fraction, increased areas of necrosis, and
resulted in a striking improvement in tumor response to treatment.
Unlike the situation for chronic hypoxic exposures, the eIF2α
pathway was also uniquely important for the survival of cells ex-
posed to repeated short cycles of severe hypoxia in vitro. ROS levels
increase somewhat during hypoxia through still-unclear mecha-
nisms, but are particularly elevated following reoxygenation (29).
ROS generated during repeated exposures to hypoxia appear to be
the source of toxicity in the eIF2α-signaling deficient cells in vitro,
as toxicity was rescued by treatment with NAC. Furthermore, our
data reveal that elevated ROS and the resulting toxicity stem from
an underlying defect in the ability of eIF2α signaling-defective cells
to induce enzymes required for cysteine uptake and GSH bio-
synthesis pathways. Together, these data demonstrate that PERK
signaling functions to increase GSH biosynthesis and prepare cells
for detoxification of ROS produced by cyclic hypoxia. The impor-
tance of this defense mechanism is demonstrated by the resulting
loss of hypoxia and increased radiation response of tumors in which
eIF2α signaling is inducibly inhibited in vivo.
Although detoxification of ROS appears to be the primary
mechanism responsible for the sensitivity of eIF2α signaling-
deficient cells to cycling hypoxia, other features of eIF2α regulation
and signaling may be relevant. Transient vessel occlusion results
in rapid and extreme hypoxia (i.e., anoxia) in a large number of
tumor cells. eIF2α signaling is well suited to respond to this stress,
because eIF2α phosphorylation and inhibition of protein synthesis
occur rapidly during severe hypoxia (Fig. S3) (35). In addition,
eIF2α/ATF4 signaling during hypoxia supports increased flux
through the autophagy pathway, aiding the clearance of ROS-
producing damaged mitochondria (22, 36).
Our results reveal a potential opportunity for development of
agents that target the PERK signaling arm of the UPR. The UPR
has been considered a target primarily for secretory tumors such as
myeloma, which experience constitutive ER stress associated with
secretion of immunoglobulins. Our data suggest that PERK in-
hibition will selectively sensitize cycling hypoxic cells due to its
requirement to protect against ROS-induced cell death. Addi-
tional work is needed to evaluate the potential of newly developed
PERK inhibitors (37) in combination with radiotherapy and
chemotherapy.
Fig. 5. PERK/UPR activation, but not HIF signaling, is required for survival after cycling hypoxia. (A) Clonogenic survival of isogenic HCT116 cells, after targeting HIF
or eIF2α signaling, exposed to normoxia or two, three, four, orfive cycles of 1 h hypoxia (O2< 0.02%) followed by 1 h of reoxygenation (mean± SEM; n= 3). (B) DHR
flow cytometry after normoxia or exposure to three orfive cycles. DHRwas added during thefinal reoxygenation period (mean± SEM; n= 3). (C) Clonogenic survival of
isogenic HCT116 cells preloadedwith theROS scavengerNAC (n= 3;mean± SEM). (D) cCT andCTHmRNAexpression levels as determinedby quantitative PCR (E). Total
GSH and free GSH were determined in control and eIF2α signaling-deficient cells (n = 3; mean ± SEM).




































U373-MG andHCT116 cells were engineered for acceptance of a single shuttle
vector (inducibly) expressing the interfering gene (flp-in T-rex system, Invi-
trogen) after doxycyline exposure. NMRI-nu (nu/nu) mice were used for
in vivo assessment of growth and radiation sensitivity. A comprehensive
description is provided in SI Materials and Methods.
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